X

Drug Profile

CX 2101A

Alternative Names: CX-2101-A

Latest Information Update: 14 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CR Double-Crane Pharmaceuticals; Ligand Pharmaceuticals
Class Antivirals; Small molecules
Mechanism of Action RNA replicase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I COVID-19 pneumonia

Most Recent Events

07 Mar 2024 Phase-I clinical trials in COVID-19 pneumonia in China (unspecified route) before March 2024 (Ligand Pharmaceuticals, Form 10-K)
22 Feb 2023 Preclinical trials in COVID-19 pneumonia in China (unspecified route), prior to February 2023
22 Feb 2023 Preclinical trials in COVID-19 pneumonia in USA (unspecified route), prior to February 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com